---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-302252"
form_type: "8-K/A"
ticker: "RVMD"
cik: "0001628171"
company_name: "Revolution Medicines, Inc."
filed_at: "2023-12-26T23:59:59+00:00"
generated_at: "2026-06-07T07:22:00.091319+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Revolution Medicines issues 54.8M shares for EQRx acquisition; pro forma shows $513M net loss

## Summary
- Acquisition closed Nov 8, 2023; issued 54.8M shares valued at ~$1.086B based on $20.02 RVMD price.
- EQRx contributed $315.7M cash and $896.6M marketable securities; accounted as capital-raising with asset acquisition.
- Pro forma combined cash & securities = $2.01B; net loss for 9M 2023: $513M; FY2022: $443M.
- One-time transaction costs of $14M and severance of $11.8M recorded as equity reductions and accruals.
- Pro forma EPS $(3.24) for 9M 2023 and $(3.27) for FY2022, on 158.5M and 135.4M weighted shares.

## SEC filing metadata
- accession: 0001193125-23-302252
- form_type: 8-K/A
- ticker: RVMD
- cik: 0001628171
- company_name: Revolution Medicines, Inc.
- filed_at: 2023-12-26T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 9.01, 2.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1628171/000119312523302252/0001193125-23-302252-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1628171/000119312523302252/d613320d8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-302252
- JSON: https://secwatch.observer/filing/0001193125-23-302252.json
- Plain text: https://secwatch.observer/filing/0001193125-23-302252.txt

## Key facts
- M&A Transactions
  Revolution Medicines, Inc. completed an acquisition involving EQRx, Inc. (closed 2023-11-09).
  - Action: acquisition
  - Counterparty: EQRx, Inc.
  - Closing: 2023-11-09
  source text: reporting under Item 2.01 the completion of its previously announced acquisition (the "Acquisition") of EQRx, Inc.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1628171/000119312523302252/0001193125-23-302252-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.